Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.

  • 2009-01
  • Antimicrobial agents and chemotherapy 53(1)
    • Kaori Tanaka
    • Hiroshige Mikamo
    • Kenichi Nakao
    • Taku Ichiishi
    • Takatsugu Goto
    • Yuka Yamagishi
    • Kunitomo Watanabe

Study Design

Population
63 reference species
Methods
The antianaerobic activity of tomopenem, a new longer-half-life parenteral carbapenem, was compared with other carbapenems
The antianaerobic activity of tomopenem, a new longer-half-life parenteral carbapenem, was compared with other carbapenems. Tomopenem showed broad activity against 63 reference species. The activity of tomopenem against 293 clinical isolates was potent (MIC(90), 0.06 to 4 microg/ml) and comparable to those of meropenem and doripenem and more potent than that of panipenem.

Research Insights

  • Tomopenem showed broad activity against 63 reference species. The activity of tomopenem against 293 clinical isolates was potent (MIC(90), 0.06 to 4 microg/ml) and comparable to those of meropenem and doripenem and more potent than that of panipenem.

    Effect
    Beneficial
    Effect size
    Moderate
Back to top